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1 RESEARCH FRAMEWORK 
 
This study investigates whether risk haplotypes of highly associated regions in PTPN3 gene 
in dogs suffering from immune mediated rheumatic disease, might affect the regulatory 
potential and expression levels of this gene influencing the phenotype. 
 
1.2 Aim of the study 
 
The overall aim of this thesis is to identify causative mutations that may alter PTPN3 gene 
expression in NSDTRs with risk for IMRD. Risk haplotypes are associated with dogs 
expressing ANA positivity and phenotypic signs of illness. It was previously shown that 
dogs from the breed Nova Scotia duck tolling retriever (NSDTR) reveal a high degree of 
susceptibility to autoimmune rheumatic diseases.  
 
   Specific aims: 
 
      1.   Bioinformatics analysis of 3’UTR and the associated region located in intron 18                 
of PTPN3 gene and DNA sequencing analysis of regions of interest. 
 
    2. Determine functional differences between risk and protective haplotype variants of 
3´UTR and intron 18 regions of PTPN3 gene in NSDTRs, using recombinant DNA 
techniques, molecular cloning, transient transfection of Jurkat T-cells and MDCK cells, 
reporter gene assays and RNA degradation analysis will be performed to develop this study.  
 
1.3 Introduction 
 
In normal individuals the immune system should be self tolerant. This is achieved by a 
number of mechanisms that prevent B and T lymphocytes from becoming self-reactive. 
Autoimmunity starts developing when an adaptive immune response tolerance breaks down 
and reacts to self-antigens, causing an inflammatory reaction and eventual tissue damage. 
Autoimmunity can have systemic or regional consequences, as it is seen in systemic lupus 
erythematosus (SLE), affecting multiple tissues and organs (Janeway et al., 2005).   
 
 NSDTRs have been shown to be associated with a strong genetic predisposition to different 
autoimmune diseases, including immune-mediated rheumatic disease (IMRD) and steroid-
responsive meningitis arteritis (SRMA). IMRD and SRMA are considered to be part of the 
same disorder, canine SLE-related disease complex (Jokinen, 2011). Regardless of the high 
prevalence of autoimmune disorders in dogs, the genetic background seems to be shared by 
several associated regions containing different genes, making the identification of causative 
ones a difficult task. A recent genome-wide association study (GWAS) revealed that, four 
of the strongest candidate genes (PPP3CA, HOMER2, DAPP1 and PTPN3) are highly 
associated with dogs suffering from IMRD. Apparently, these same genes seem to be also 
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involved in regulation of nuclear factor of activated T cells (NFAT) pathway (Wilbe et al., 
2009). 
The strongest associated region is located on chromosome 11 and contains only one gene, 
PTPN3. Targeted re-sequencing of this gene in healthy and diseased dogs helped to define 
the risk haplotype. Encoded PTPN3 protein seems to play an important role in TCR-
signaling inhibition and transduction and is one of the most associated genes in NSDTRs 
with IMRD (Wilbe et al., 2010). Analysis of gene expression in peripheral blood 
mononuclear cells (PBMCs) revealed that dogs carrying risk haplotypes express much 
lower PTPN3 mRNA levels (up to eight times fold) compared to dogs with protective 
haplotype (Wilbe et al., 2013). This evidence suggests that the major effect might be 
associated with the regulation of gene expression. Associated variants from risk haplotype 
seem to be spread out in a few regions with regulatory potential, including the PTPN3 
promoter, intronic enhancers and mRNA stability in the 3’UTR. SNPs in introns and 
3’UTRs may have a strong influence in transcription or translation as well as a direct effect 
on mRNA stability or translation efficiency (Wilbe et al., 2013). Besides, PTPN3 seems to 
be involved in a novel T-cell activation pathway, NFAT as a negative regulator of TCR 
(Wilbe et al., 2013).  
 
Although many genes have been associated with SLE, functional variants for most of these 
genes have not yet been identified, and that is why the biology underlying them is still 
unknown. It is of extreme importance to understand not only how they function and interact 
with each other, but also what happens exactly if one of them is missing or overrepresented. 
This study aimed to identify causative mutations and determine the molecular effects 
leading to down-regulation of PTPN3 gene expression in NSDTRs with the risk haplotype.  
 
Transient transfection analyses in MDCK and Jurkat T cells were performed using a series 
of constructs containing dog PTPN3-intron 18 and 3’-UTR ligated to a luciferase reporter. 
We have developed functional analysis using in silico tools and recombinant DNA 
techniques like PCR, molecular cloning, plasmid DNA purification, transformation in E. 
coli and transfection of two different mammalian cell types, luciferase expression analysis 
and RNA degradation assays. This study was undertaken to study genetic impact of 
associated variants of PTPN3 with susceptibility to IMRD and to assess the functional 
implications of this association. 
 
2 REVIEW OF LITERATURE 
 
2.1 The Dog as experimental model for Human Inherited disorders 
 
Dogs have been proven to be a very important model organism for mapping human 
complex diseases (Lindblad-Toh et al., 2005). Because a similar spectrum of diseases that 
occur spontaneously over the course of their lives as well as advantageous population 
structure (Ostrander et al., 2000). Ancient dogs were initially domesticated from wolves 
since around 15,000 years ago, most likely through multiple domestication events. Its 
genome has short-range Linkage Disequilibrium (LD) and short haplotype blocks that 
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would be expected due to its large size and long time period since domestication bottleneck 
(Karlsson and Lindblad-Toh., 2008). 
 
The modern dog seems to be the domestic species with the most diversified phenotypic 
variations. There are currently more than 400 different breeds and each one of these seem to 
be characterized by unique behavioral and physical traits that have evolved in sequence of 
two main important population bottlenecks, the first during breed creation and second 
during the World Wars or depression as well as infectious disease breakouts, reducing the 
effective breeding population to only a few dogs. Strong artificial selection and tight 
inbreeding had also accumulated recessive disease alleles (Karlsson and Lindblad-Toh, 
2008). These events had lead to unexpected health impairments, especially amongst 
purebred dog populations. Enrichment of risk alleles due to random fixation during 
bottlenecks, hitchhiking of unwanted mutations together with desirable traits and pleiotropic 
effects of selected variants had definitely contributed to disease incidence in modern dogs 
(Karlsson and Lindblad-Toh., 2008)).  
 
The majority of canine breeds are quite recent (less than 200 years old) revealing extensive 
degree of linkage disequilibrium and long haplotype blocks within them, this due to the fact 
that only a small subset of chromosomes was selected from a given group of domestic dogs. 
The long-range patterns that were carried on these chromosomes became common within 
different breeds, creating long-range LD estimated at several megabases, 40–100 times 
longer than in humans (Lindblad-Toh et al., 2005). These patterns make canine models 
excellent for GWAS and mapping, where fewer markers and smaller number of individuals 
within a population are needed compared with human studies. In 2005, not only the dog 
genome was completely sequenced but also the development of resources needed for 
association mapping. Understanding canine haplotype structure and definition of dense SNP 
map are currently powerful tools used for high-throughput SNP genotyping of the dog. 
Besides, dogs share basically the same number of genes as humans, most of which are 1:1 
orthologues (Lindblad-Toh et al., 2005). Identification of genes and causative loci in dogs 
can help to better understand pathogenesis and new pathways associated to the same disease 
in humans, opening windows to development of novel diagnostic tools, gene tests and new 
treatments and drugs. In addition, dissecting the network of interacting loci that cause 
diseases with complex, polygenic inheritance in dogs, and defining their severity, will give 
insight into the considerably more complex web underlying human diseases. 
 
IMRD has a high degree of similarity with its homologue human disorder, and shows a 
complex pattern. Furthermore in NSDTRs there is a high prevalence of immune-mediated 
diseases including a disease-complex that resembles human systemic lupus erythematosus. 
 
2.2 Shared Autoimmune disorders between dogs and humans 
 
According to the Online Mendelian Inheritance in Animal (OMIA) database the information 
retrieved in 11.03.2013, showed that there are 587 inherited traits/diseases in dogs, from 
which 303 are considered as potential disease models for human diseases. The list of 
autoimmune diseases in dogs shared with humans is relatively long and includes alopecia, 
diabetes mellitus, epidermolysis bullosa, autoimmune hemolytic anemia, hypothyroidism, 
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myasthenia gravis, pancreatic insufficiency, pemphigus, systemic lupus erythematosus 
among others (Table 1). Pure-bred dogs seem to be the most affected.  
 
 
Human autoimmune disease 
 
Canine autoimmune disease 
Alopecia areata Alopecia 
Anonychia-onycodystrophy Onychodystrophy 
Diabetes mellitus Diabetes mellitus 
Epidermolysis bullosa Epidermolysis bullosa 
Haemolytic anaemia, autoimmune Haemolytic anaemia, autoimmune 
Hypoadrenocorticism (Addisson) Hypoadrenocorticism 
Hashimoto’s thyroiditis Lymphocytic thyroiditis 
Myastenia gravis Myastenia gravis 
Narcolepsy Narcolepsy 
Pancreatic insufficiency, Exocrine Pancreatic insufficiency, exocrine 
Pemphigus foliaceus Pemphigus  
Polyglandular autoimmune syndrome, type II Polyglandular autoimmune syndrome, type II 
Systemic lupus erythematosus Systemic lupus erythematosus 
Table 1 Common autoimmune diseases shared between human and dogs (http://omia.angis.org.au, accessed March, 
2013). 
 
2.3 Systemic Lupus Erythematosus in Humans and Dogs 
 
Systemic lupus erythematosus (SLE) or lupus, is a human autoimmune disease 
characterized by a Type III hypersensitivity reaction caused by systemic deposition of 
autoantibody-immune complexes, where potentially any part of the body might be affected. 
Similarly to other autoimmune disorders, the immune system in an SLE-affected patient 
directs its attack to the body's self-tissues, cells and molecules. Localization of an 
inflammatory reaction followed by tissue damage characterizes the different disease 
phenotypes (James et al., 2005). The progression of the disease cannot be predicted and is 
characterized by alternating periods of illness and remissions.  
 
In SLE, the immune system starts producing antibodies against self-proteins and chromatin 
present in the cell nucleus. This event may eventually be triggered by different 
environmental factors (ultraviolet light, drugs, and viruses). These environmental stimuli 
may cause destruction of cell membranes and expose nuclear material like chromatin and 
nuclear proteins. In some individuals the immune system directs its defense against these 
nuclear-related proteins producing antibodies against them (Kindt et al., 2007).  
 
There is no current treatment for lupus, and ongoing research is being conducted worldwide 
towards identification of causes (both genetic and environmental) and effective treatments 
in order to increase life quality of affected human and animal patients. 
 
Similar conditions are also observed in other mammals including the dog. SLE-related 
diseases like immune-mediated rheumatic disease can be observed in German Shepherds, 
English Springer Spaniel, Boxer and Petit Basset Griffon Vendeen and Nova Scotia Duck 
Tolling Retrievers. NSDTRs were initially selected and developed in the end of 19th 
century in the Canadian region of Nova Scotia as a duck hunting and retrieving dog. During 
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initial stages of breed selection a couple of important Canine Distemper Virus outbreaks 
significantly reduced size of the NSDTR population to only a few individuals. There is 
some evidence supporting that progenitors that perpetuated this breed derived from the 
stock that survived this devastating canine viral outbreak resulting in a genetic bottleneck 
and a strong founder effect for the genetic risk factors of SLE (Strang et al., 1996). NSDTR 
seems to be amongst the most susceptible dog breeds to a specific set autoimmune disorders 
designated SLE-related diseases. Immune-Mediated Rheumatic Disease (IMRD), Steroid-
Responsive Meningitis Arteritis (SRMA) and Hypoadrenocorticism. 
 
No epidemiological studies have to date been reported in the scientific literature regarding 
SLE-related disease prevalence in dogs, however this condition seems to be relatively rare 
in dogs in general.  
 
A study developed by Hansson-Hamlin, SLU and colleagues while working at Clinical 
Pathology department of the Uppsala University for ANA positive tests suggest that the 
canine breed NSDTRs are much more susceptible to IMRD with 26% incidence among 
total cases from different breeds (Jokinen, 2011). 
SLE-related disease complex includes both IMRD and SRMA.  Epidemiological and 
clinical studies suggest the prevalence of symptoms associated with chronic 
musculoskeletal signs with stiffness and pain from different joints, as well as aseptic 
meningitis, reporting high frequency in this breed (Hansson et al., 2009). One of the most 
important diagnostic criteria of SLE is the presence of high levels of circulating antinuclear 
antibodies (ANA) that can be detected by direct immunofluorescence-antinuclear antibody 
test IIF-ANA.  Similarly to humans, it has already been attempted to identify a clear set or 
list of uniform and consistent phenotypes for SLE-related conditions in the dog but 
currently no such phenotypic criteria have been successfully defined (Hansson et al., 2009). 
Clinical signs may range from polymyositis, fever, neurological disorders, anemia, skin 
disorders and thrombocytopenia (Chabane et al., 1999). 
 
2.4 Immune-mediated rheumatic disease (IMRD) and Steroid-responsive 
meningitis arteritis (SRMA) in NSDTRs 
 
In human patients, rheumatic conditions develop secondary to autoimmune factors where 
clinical problems affect connective tissues, soft tissues and articular joints (Hansson et al, 
2009). Similarly, affected dogs seem to share the same clinical signs revealing ANA 
positivity in 70% of cases and signs of polyarthritis in 100% of cases (Jokinen, 2011). Other 
commonly detected signs may include fever, dermatological disorders as well as liver and 
kidney problems. Blood analysis testing for the presence of rheumatoid factor can be 
performed, however, rheumatoid factor is in some cases present in dogs without rheumatoid 
arthritis, and not all dogs with rheumatoid arthritis test positive for the factor. Radiographic 
evaluation of the affected joints can be used for diagnostic purposes and typically show the 
morphological changes in bones - The joint surfaces are frequently irregular and bony spurs 
coming off of the bone are commonly seen. Another commonly used diagnostic method is 
to analyze the synovial fluid and determine whether inflammatory cells are present in large 
numbers, and whether the synovial fluid is less viscous than normal and may appear cloudy 
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(Hansson et al., 2009). 
NSDTRs reveal the onset of this condition between 2 months and 3 years of age and 
comparing to other breeds the frequency is markedly higher (Hansson et al., 2009).  
In another SLE-related disease, SRMA, clinical signs are caused by a combination of 
meningitis and arteritis of leptomeningeal vessels. Two different forms of SRMA may 
develop in dogs. The acute, the most common and typical one, characterized by episodes of 
hyperesthesia along vertebral column and cervical rigidity, resulting in difficulties to turn 
and lower the head, stiff gait, pyrexia, depression and anorexia (Tipold et al., 1994) 
mimicking intervertebral disc disease. Cerebrospinal fluid analysis reveals high numbers of 
polymorphonuclear pleocytosis and elevated protein concentration and red blood cells 
secondary to leakage from damaged vessels. Cerebrospinal fluid analysis regarding 
bacterial presence is routinely negative although it is not a commonly used diagnostic 
method. In some dogs, meningitis may also affect the meninges of the brain and the choroid 
plexus. Computed tomography scan or magnetic resonance imaging might reveal high 
contrast enhancement of the meninges. A second, more chronic relapsing form of SRMA 
has more reserved prognoses, with meningeal fibrosis secondary to initial inflammation that 
may obstruct cerebrospinal fluid flow or occlude the vasculature and potentially causing 
secondary hydrocephalus or ischemia of nervous system parenchyma (Summers et al., 
1995). Other neurological signs include variable degrees of paresis and ataxia, menace 
deficits, anisocoria or strabismus and mild to moderate levels of mononuclear cells or 
mixed cell population in cerebrospinal fluid and eventual raise in total protein (Tipold, 
1995). Most of the affected dogs have elevated IgA levels in both blood serum and 
cerebrospinal fluid, a finding that is most likely associated to immune system deregulation 
(Felsburg et al., 1992). In some situations, dogs may develop signs of polyarthritis, which is 
also present in all cases of IMRD-diseased dogs. The onset of the first signs of SRMA may 
usually develop at 4 to 19 months of age, and a lifelong corticosteroid therapy may be 
necessary to inhibit recurrence, which might happen in around 50% of all affected dogs. An 
epidemiological study developed in a Norwegian population of NSDTRs revealed an 
estimated prevalence of SRMA of around 2,5%. This value however, is most likely 
underestimated (Anfinsen et al., 2008). In some cases, due to complications or 
consequences of corticosteroid long-term therapy, some dogs have to be euthanized.  
2.5 Genetics of SLE-related disease in NSDTRs 
 
The genetics of SLE is still not yet still completely understood. Developing genetic studies 
and subsequent functional assays are making efforts to acquire a better understanding of the 
etiology of this disorder. Although human studies reveal that SLE is pedigree related, no 
single unique causative gene has yet been identified. Instead, multiple genes may have a 
strong influence on individual’s chances of starting to develop SLE when triggered by 
environmental factors (Martens et al., 2009). Most frequently, associated allelic variants 
seem to be linked to both increase in disease risks and protection as well (Erman, 2001). 
Besides, studies focusing on genetic susceptibility to any given autoimmune disease are also 
complicated by the presence of protective haplotypes that seem to mask the susceptibility 
and completely inhibit the risk imposed by the susceptibility or risk haplotypes  (Morel et 
al., 1999). Monogenic autoimmune diseases are very rare (Ahonen, 1990). Several genes 
having small effects characterize polygenic nature of autoimmunity, and some of these 
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genes and pathways have already been identified. Most of the susceptibility genes are 
strongly related to apoptosis, signaling, auto antigen availability and clearance, and 
cytokine and co-stimulatory molecules expression. Major histocompatibility complex MHC 
class II locus, T cell receptor (TCR) regulation and a few others for example, have been 
strongly associated with autoimmunity in canine models (Wilbe et al., 2010).  
As indicated above, incidence of autoimmune disorders, in particular SRMA and IMRD are 
overrepresented in the breed NSDTR (Hansson-Hamlin, 2009). A recent study developed 
by Wilbe aiming to determine whether these are indeed two different diseases sharing 
common genetic risk factors or on the other hand, represent two separate disorders was 
performed using GWAS, to identify genetic risk factors associated with disease. Five loci 
were successfully identified as associated with SLE-related disease complex using a two-
stage mapping strategy. All of the associated regions contained several genes making 
identification of causative ones very difficult. Four very strong candidate genes were 
identified (PPP3CA, HOMER2, DAPP1 and PTPN3) that seem to be involved in regulation 
of nuclear factor of activated T cells (NFAT) pathway (Fig. 1).  
 
 
Figure 1. Associated regions located on four chromosomes for ANA-positive SRMA  
and IMRD dogs (CFA 3, 8, 11 and 24). From: Wilbe 2009, Nature Genetics. 42(3):250-254 
 
Fine-mapping was also performed with the purpose to validate associated regions by 
addition of more NSDTR cases and controls. Three loci located on chromosomes 3, 11 and 
24 associated with ANA-positivity were strongly validated, with p-values in the range 10-11-
10-13 (Wilbe et al., 2010). 
Expectedly, a few loci with a strong effect each may affect the development of this 
immune-mediated disease complex in NSDTRs and a combination of these genetic risk 
factors might be sufficient to predispose to this disease (Wilbe et al., 2010).  
Further analysis associating GWA risk loci on CFA 3, 8, 11, 24 and 32 with ANA speckled 
phenotype dogs revealed strong associations to CFA 11 and 32. The region on chromosome 
11 covering the PTPN3 gene comprised a haplotype highly associated to ANA speckled 
(ANAS) dogs (Wilbe et al., 2013).  
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2.6 Protein Tyrosine Phosphatase Non-Receptor type 3 (PTPN3) Gene 
 
In Humans, PTPN3 is located in Chromosome 9: 112,137,974-112,260,593 reverse strand. 
So far, 7 alternatively spliced transcript variants encoding different isoforms have been 
found for this gene (www.ensembl.org, accessed April 2013), and comprises 122,620 bases. 
 In the dog, and according to Ensembl Canis lupus familiaris version 70.31 (CanFam3.1) 
PTPN3 is also encoded on reverse strand of chromosome 11 and comprises 122,2 Kb, 26 
exons from which 25 are coding exons and 913 amino acids (www.ensembl.org, accessed 
March 2013). PTPN3 gene is part of the same family as PTPN22, which was previously 
associated as a major genetic risk factor for SLE and other autoimmune diseases in humans 
(Chung, 2007). 
 
2.7 Genetic variants in PTPN3 gene in NSDTRs 
 
A four SNP haplotype out of the 15 most highly associated SNPs (11:67,516,041, 
11:67,538,032, 11:67,538,806 and 11:67,583,604) across the PTPN3 gene in CFA 11 was 
used for correlation of mRNA expression levels between healthy and severely diseased 
IMRD and ANAS dogs, and an 8-fold down regulation of mRNA levels (p=0.013) was 
identified in dogs carrying the risk haplotype (Wilbe et al., 2013).  A four SNP haplotype 
was generated across PTPN3 (fig. 2) and most severe cases of IMRD that lead dogs to death 
were homozygous for the risk haplotype G/G-T/T-C/C-A/A (11:67,516,041, 11:67,538,032, 
11:67,538,806 and 11:67,583,604, respectively). The protective haplotype for the same 
SNPs was defined by A/A-G/G-T/T-G/G, whereas the only risk haplotype present in 
healthy dogs was G/A-T/G-T/C-A/A and this haplotype was not correlated with any 
significant down-regulation of relative mRNA levels in PTPN3 expression (Wilbe et al., 
2013).  
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Figure 2. A 16 SNP 97 Kb haplotype overlapping PTPN3 gene. The indicated 
four top most associated SNPs were previously analyzed for correlation to 
mRNA expression in three different haplotypes: two synonymous SNPs in exon 3 
and 18, one on intron 18 and one in the 3’UTR (Wilbe et al. 2013) 
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2.8 PTPN3 and Tyrosine Phosphorylation in TCR Signal Transduction 
 
Tyrosine phosphorylation classified by four different families is represented by 107 genes 
in the human genome (Alonso et al., 2004). However, only 81 of these are known to be 
catalytically active and dephosphorylate tyrosine residues. The domain of PTP has around 
280 amino acids and is characterized by the signature motif (I/V)HCxxGxxR(S/T), that 
constitutes an important part of the phosphate binding pocket. Besides this, there are still 9 
more motifs spread along the PTP primary sequence domains involved in substrate 
recognition and catalysis that are highly conserved (Andersen et al., 2005). The PTP 
families can be subdivided into receptor-like and non-receptor PTP (Bauler et al. 2008). 
The latter consists of 17 members, including PTPN3; most of them have a modular domain 
that affects localization and function. PTPs (and from which PTPN3 is part of) are signaling 
molecules that regulate a multitude of cellular processes like cell growth and differentiation, 
mitotic cell cycle, and oncogenic transformation. P97, a cell cycle regulator involved in a 
variety of membrane related functions, has been shown to be a substrate of this PTP 
(www.ncbi.nlm.nih.gov/refseq/, accessed April 2013). 
 
PTPN3 consists of an NH2-terminal FERM domain, a central PDZ domain, and a COOH-
terminal PTP domain. Both PDZ and FERM bind the cytosolic domains of transmembrane 
proteins as well as phospholipids PI(4,5)P2. In molecular biology, the FERM domain is a 
common protein domain involved in localizing proteins in the plasma membrane (Chrishti, 
1998). The FERM domain, is located at the N terminus of PTPN3 and seem to be required 
for PTP membrane localization in T cells (Bauler et al., 2008). Studies suggest that the 
phosphatase expressed by the PTPN3 gene also participates in multiple functions in signal 
transduction pathways depending on cell contexts. Human PTPH1 encoded by the PTPN3 
gene acts in TCR-signaling and transduction as a negative regulator dephosphorylating the 
immune tyrosine-based activation motifs (ITAM) in the TCRζ chain. Downstream in this 
pathway it will potentially inhibit activation of nuclear factor of activated T- cells (NFAT) 
(Sozio et al., 2004). The previously detected reduction of the PTPN3 mRNA levels in dogs 
carrying the risk haplotypes may cause a permanent activation of TCR signaling and lead to 
development of autoimmune disorders (Wilbe et al., 2013). 
 
T lymphocytes originate from a common hematopoietic stem cell progenitor in bone 
marrow to all different blood cell types. Unlike B cells, which mature within the bone 
marrow, T cells migrate to the thymus gland where they achieve maturation. During this 
process within the thymus, the T cell will start to express a unique antigen-binding 
molecule, called the T-cell receptor (TCR), on its membrane (Kindt et al., 2007). 
The signaling pathways stimulated by these receptors use PTP to transduce such signals. 
Particular signals originating from TCR seem to be associated at least partially with T cell 
maturation and function (proliferation, differentiation growth, migration, B cell helping and 
target cell lysis) (Bauler et al., 2008). T cells express around 14 non-receptor PTPNs and 
they are considered as negative regulators of TCR signaling (Musteling, 2005). In a study 
conducted by Gjorloff-Wingren, over-expression of PTPN3 gene in T cell leukemia cell 
lines had deeply inhibited TCR-dependent signal transduction leading to constitutive 
activation of the T cell growth promoter cytokine IL-2. This interesting finding strongly 
suggests that PTPN3 may inhibit TCR-signaling in T cell leukemia, through 
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dephosphorylation of the plasma membrane-localized substrate, contributing to the idea that 
PTPN3 acts a negative-regulator of TCR signaling by dephosphorylating the TCR (Bauler, 
2009).  
 
4 MATERIALS AND METHODS  
 
4.1 Primer Design 
 
For assistance with designing and calculating the Tm of primers Amplify 3.1 software was 
used. 
Primer design for Intron 18 for sequencing; 5’-ACCATCTGCATTCAGGTGTCGT-3´ 
(PTPN3-f-in18-1), 5’-AGTAACGCACATTATCTACATGCTAC-3’ (rev-PTPN3-int18-1), 
(amplicon with 1311 bp). 5’- GAAGAGCAAACACCATAAAGCA-3’ (PTPN3-f-int18-2) 
5’-GCAGCGTGTCCATCAGAAATC-3’ (Rev-PTPN3-int18-2), (amplicon with 1403 bp), 
and 5’-TATCCTTGGTCTGTAGCTGTTTCA-3’ (Rev-PTPN3-in18-3), (amplicon with 715 
bp) 
Primers for intron 18 with restriction sites for cloning,; 
5’GTACCgagctcAAGTGGGAACACAGGAGATTCG-3’ (in18-f-clon1-SacI), 5’-
GTACCagatctCCTTGGAGAGACACTACTCAAAACT-3’ (Rev-in18-clon-BglII) 
(amplicon 1 with 1613 bp)  and 5’, covering 7 SNPs (Table 2) 
GTACCgagctcTATACATTGTAAACACTGTAAAACTCA-3’ (in18f-clon2-SacI) with 
same 5’-GTACCagatctCCTTGGAGAGACACTACTCAAAACT-3’ (Rev-in18-clon-BglII) 
(for amplicon 2 with 838 bp). 
Primer design for PTPN3, 3’UTR, for sequencing: 5’-
AGCTGGACCTCAGGGCATATTTAT-3’ (PTPN3-3'UTR-forw-1), 5’-
GTTCCCATGGTTCCATGACTAGAT-3’ (Rev1-PTPN3-3'UTR), 5’-
CAACTAAATGTGCTAAGTCTGGAGATA-3’ (Rev2-PTPN3-3'UTR): Amplicon 1 with 
Rev1 primer = 1174 bp and amplicon 2 with with Rev2 primer = 1785 bp. 
Primers for cloning of 3’UTR: 5’ GACAACTGTGAAAAACGTTCATTC-3’ (PTPN3-
3UTR-for-clon), amplicon with Rev2-1591 bp covering three SNPs (Table 2);  
5’-GTCGCGGATCCCAACTAAATGTGCTAAGTCTGGAGATA-3’ (Rev2-PTPN3-
BamH1) 
 
 
4.2 PCR amplification 
 
For primer testing and DNA amplification for sequencing purposes, Platinum Taq DNA 
Polymerase (Invitrogen) was used. This is a widely used hot-start enzyme for robust and 
reliable amplifications. Platinum Taq is an antibody-mediated, hot-start enzyme that 
provides high PCR specificity ranging from cloning to genotyping to mutagenesis 
(Invitrogen, 2013). 11 DNA samples from risk and protective haplotypes were diluted in a 
25 μl reaction mixture containing 0,1μl Platinum Taq, 1 μl dNTPs, 0,8μl MgCl2, 2,5μl 10x 
PCR Rxn Buffer (Invitrogen) and 1 μl primers for 3’UTR (four sets) and intron18 (three 
sets).  PCR conditions were as follows: 95°C for five min, followed by 45 cycles of 95°C 
for 15 sec, 60°C for 15 sec, then 72°C for 2 min and 72°C for 3 min final extension and 4°C 
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final hold. PCR product reactions were sent for sequencing at Sanger Sequencing Service 
(Uppsala Genome Center) after post PCR purification. PCR product purification was 
achieved using 0.1μl Exonuclease I (Fermentas) and 0.1μl Alkaline Phosphatase (Promega) 
added to 2μl Buffer SAP (Fermentas) per 25μl tube reaction, and incubated at 37°C for 1 h 
followed by 85°C for 15 min. Exonuclease I is a single strand exonuclease that allows 
degradation of primers still existent in the reaction tubes. Alkaline phosphatase on the other 
hand, allows removal of dNTPs still present in the PCR reactions.  As for PCR 
amplification for cloning, incorporation fidelity for high fidelity amplification is an 
important asset. Therefore, we used a thermostable enzyme with proofreading to allow good 
fidelity in amplification reactions. Pfu proofreading enzyme has the potential to offer three- 
to six fold higher fidelity than standard DNA polymerase (Cline et al., 1996). PCR 
amplicons generated with proofreading Pfu polymerases are blunt ended giving an A-tail 
for T-vector subcloning (Knoche, 1999). DNA from risk and protective haplotypes was 
diluted in a 25 μl reaction mixture containing pfu Buffer, 1 μl dNTPs, 0,5 pfu ultra enzyme 
and 1 μl primers for 3’UTR and 2 amplicons of intron18 region. PCR conditions were as 
follows: 95°C for five min, followed by 45 cycles of 95°C for 15 sec, 60°C for 15 sec (57°C 
for intron 18) then 72°C for 2 min and 72°C for 4 min final extension and 4°C final hold. 
The oligonucleotide primers for PTPN3 3’UTR and intron18 were synthesized for us by 
IDT and were as previously described.  
 
4.3 Analysis of PCR products by Agarose Gel Electrophoresis 
 
PCR products were resolved using 1% agarose gel electrophoresis in TAE (Tris-Acetate-
EDTA) Buffer. Gels were run at 120 volts for 20-25 min. To make the gels, 0,5g of 
Ultrapure agarose powder (Invitrogen) was measured in a 300ml conical flask and 50ml 
1xTAE Buffer added. The flask was heated in a microwave oven until agarose was 
dissolved . 3 μl SYBR Safe DNA Gel Stain, a safe nucleic acid stain for detection DNA in 
agarose gels, was added to the flask and the gel poured into the gel tray with the comb. Gels 
were allowed to set and combs removed. 4 μl PCR products were loaded into the wells with 
≈3μl of 6x Loading DNA Dye  (Thermo Scientific). 2μl of GeneRuler 1Kb DNA ladder  
(Thermo Scientific) was also loaded for molecular weight reference. Gel was subsequently 
placed against UV Light using BioRad CCD camera image station and Quantity-One 1D 
analysis software for image capture. 
 
4.4 Sequencing of PTPN3 exon 18, intron 18 and 3’UTR regions 
 
Results from sequencing were analyzed using Sequencher software, where all 11 samples 
including 4 protective haplotypes, 2 risk heterozygous and 5 risk homozygous haplotypes 
were genotyped and compared for 1 SNP in exon 18, 7 SNPs in the intron 18 and 3 SNPs 
for 3’UTR (Table 2). 
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Exon18 
           
Dog ID  
Dog1 
(913) 
Dog2 
(848) 
Dog3 
(658) 
Dog11 
(634) 
Dog4 
(828) 
Dog5 
(900) 
Dog6 
(72) 
Dog7 
(73) 
Dog8 
(81) 
Dog9 
(100) 
Dog10 
(267) 
SNP1 
                 
67538806 T/T T/T T/T T/T C/T C/T C/C C/C C/C C/C C/C 
  Intron18            
             
Dog ID  
Dog1 
(913) 
Dog2 
(848) 
Dog3 
(658) 
Dog11 
(634) 
Dog4 
(828) 
Dog5 
(900) 
Dog6 
(72) 
Dog7 
(73) 
Dog8 
(81) 
Dog9 
(100) 
Dog10 
(267) 
SNP1 67538032 G/G G/G G/G G/G G/G     T/T T/T T/T T/T 
SNP2 67537924 C/C C/C C/C C/C A/C    A/A A/A A/A A/A A/A 
SNP3 67537493 C/C C/C C/C C/C C/T C/T T/T T/T T/T T/T T/T 
SNP4 67537363 C/C C/C C/C C/C C/T C/T T/T T/T T/T T/T T/T 
SNP5 67537177 A/A A/A A/A A/A A/G A/G G/G G/G G/G G/G G/G 
SNP6 67536944 C/C C/C     C/T     T/T T/T T/T   
SNP7 67536642 A/A A/A A/A   A/C     C/C C/C C/C C/C 
 3’UTR            
Dog ID  
Dog1 
(913) 
Dog2 
(848) 
Dog3 
(658) 
Dog11 
(634) 
Dog4 
(828) 
Dog5 
(900) 
Dog6 
(72) 
Dog7 
(73) 
Dog8 
(81) 
Dog9 
(100) 
Dog10 
(267) 
SNP1 
                        
67516230 G/T G/C G/G G/C  G/G ? G/G G/G G/G G/G G/G 
SNP2 67516211 T/T T/T T/T T/T T/T ? T/T T/T T/T T/T T/T 
SNP3        67516041 A/A  A/A A/A A/A G/A G/A G/G G/G G/G G/G G/G 
 
                      PTPN3 Haplotypes  
Protective :  A/A-G/G-T/T 
     Risk homozygous:  G/G-T/T-C/C 
Risk heterozygous:  G/A-G/T-C/T 
  
 
     Table 2: PTPN3 Sequencing analysis of different SNP genotypes of protective and risk haplotypes for exon 18, intron 18 and          
3’UTR  from NSDTRs. Analysis performed with Sequencher software. Highlighted indicates SNPs associated with defined 
haplotypes. 
 
                                  
4.6 Molecular Cloning  
 
 DNA inserts from 3’UTR and intron 18, and pGL3 promoter plasmid were subject to 
different steps of purification and digestion with specific restriction enzymes prior to 
ligation.  
For the 3’UTR region, DNA from protective and risk haplotypes were digested with BamHI 
only. pGL3 promoter was cleaved in two distinct restriction sites: BamHI and XbaI, leading 
to removal of 260 bp SV40 late poly(A) signal. XbaI end of plasmid was “polished” with 
pfu Ultra turning it into blunt ends on that side and kept as sticky ends on BamHI side 
(Fig.3).  
 
For intron 18 region, DNA from both protective and risk haplotypes and pGL3 were 
digested with SacI and BglII. A cleavage after synthetic poly(A) signal pause site was 
created for the insertion of the 2 intron 18 amplicons (Fig. 4). 
To measure nucleic acids concentration (3’UTR, intron 18 inserts and pGL5 plasmid) 1μl of 
the samples was analysed on a NanoDrop ND-1000 Spectrophotometer according to the 
manufacturers instructions. 
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Ligation was performed according to manufacturer protocol with T4 DNA ligase (Thermo 
Scientific) and PEG in a 20 μl volume at a molar ratio of 3:1 of DNA to vector and 
incubated at 12°C for 15 min and then 22°C for 60 min. 
 
Restriction sites for 3’UTR insert in pGL3 promoter vector: 
 
 
BamHI 
 
XbaI  
 
 
 
Figure 3. Schematic representation of pGL3 promoter vector with restriction sites and  
1.6 Kb insert location for 3’UTR. 
  
 
 
 
 
 
Restriction sites for intron 18 insert in pGL3 promoter vector: 
 
 
SacI 
 
BglII 
 
 
 
 16 
 
Figure 4. Schematic representation of pGL3 promoter vector with restriction sites for two 
intron 18 inserts (1613bp and 838bp) ligation. 
 
 
50 μl chemically competent E. coli One Shot TOP10 (Invitrogen) cells were thawed on ice 
for each ligation/ transformation. 4 μl of each ligation reaction was pipetted directly into 
each vial of competent cells tube and tapped to mix. The tubes were then left on ice for 25 
min, heat shocked at 42° C for exactly 30 sec in water bath and placed back on ice. 250 μl 
of pre-warmed S.O.C medium was added to each vial using sterile technique. Vials were 
then left in the shaker incubator at 225 rpm, 37°C for exactly one hour.  Tubes were taken 
out of the shaker, and the contents streaked onto the selective LB (50 μg/ml Ampicillin) 
separate and labeled agar plates with 20 μl and 100 μl for each transformation and 
incubated overnight at 37°C. 
In order to be sure about successful transformation of competent cells that have 
incorporated the plasmid vector pGL3 plus DNA inserts, 15 colonies from each 100 μl 
seeded petri dish plates were “picked up” with pipette tip and cultured in 1,5 ml properly 
labeled eppendorf tubes containing 150 μl of LB medium + 1μg/ml Ampicillin and 
incubated for 5-6 hours in shaker at 225 rpm, 37°C. 
Plasmid DNA was initially extracted and purified for identification of potential positive 
colonies, using phenol/chloroform. 120 μl of cell suspension were aliquoted into new 
eppendorf tubes and centrifuged for 3 min at 13 000 rpm. After removal of supernatant by 
pipetting, 30 μl of TE buffer (10 mM Tris-Cl pH 8, 0.1 mM EDTA) were added to each 
tube and vortexed for 30 sec. 30 μl of phenol/chloroform were additionally added and 
vortexed again for another 30 sec. Centrifugation of the suspension allowed separation of 
purified DNA in the upper phase, which was afterwards loaded (20 μl) in a 1% agarose gel 
together with pGL3 control plasmid vector and 1Kb DNA ladder. Successful plasmid /insert 
incorporation was promptly identified by corresponding size bands after 1% agarose gel 
running for 25 min at 120 V. pGL3 vectors with 3’UTR revealed 6.3 Kb size bands (against 
5Kb control vector and non transformed colonies), and intron 18 positive transformants 
revealed 6.6Kb (amplicon 1) and 5.8Kb (amplicon 2) size bands according to the two 
different size inserts. 1 μl of initial positive transformed cells previously aliquoted were 
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then recultured in 6 ml of ampicillin-enriched LB medium and incubated at 37°C at 200 
rpm shaker incubator for approximately 14,5 hours, until culture medium became milky in 
appearance. 
 
DNA extraction of transformed bacterial cultures for transfection was done using QIAprep 
Spin Miniprep Kit according to manufacturer’s instructions. 
The pelleted bacterial cells were resuspended in 250μl Buffer P1 and transferred to a 
microcentrifuge tube, 250μl Buffer P2 was added and mixed thoroughly by inverting the 
tube 4-6 times, 350μl Buffer N3 was added and mixed thoroughly by inverting the tube 4-6 
times and then centrifuged 10 min at 13,000 rpm to obtain a compact white pellet. 
Supernatant was then decanted into the QIAprep spin column, centrifuged for 60 sec and 
the flow through was discarded. The column was washed by adding 750μl Buffer PE and 
spinning for 1 min and then again another minute after removal of any residual wash buffer. 
QIAprep spin column was finally placed in a 1.5ml microcentrifuge tube and 50μl Buffer 
EB (10mM Tris-Cl, pH 8.5) added to the center of the spin column and left to stand for 1 
min, then centrifuged 1min to elute and collect DNA. 
 
4.6.1 Sequencing of Plasmid DNA 
 
Sequences of cloned DNA inserts were analyzed to confirm adequate integrity of alleles and 
to detect possible mutations. After PCR, all product reactions were sent for sequencing at 
Sanger Sequencing Service (Uppsala Genome Center).  
Regarding 3’UTR two different alleles in protective haplotype were used for transfection to 
determine possible functional variations between these and the risk variant (Table 3). 
 
 
      Haplotypes for cloned PTPN3 3’UTR 
2 Protective: G/A and C/A 
1 Risk homozygous: G/G 
Table 3: Alleles of 2 SNPS for 3 cloned variants of PTPN3 3’UTR-pGL3 construct. 
 
  
4.7 Transfection 
 
4.7.1 MDCK Cells 
 
Madin Darby Canine Kidney cells (MDCK), were originally obtained by S. H. Madin and 
N. B. Darby from the kidney tissue of an adult female cocker spaniel dog, in September 
1958.  The MDCK line has been mainly used as a general model for epithelial cells such as 
epithelium (Hamamatsu Learning Center, April 2013), in this case they are useful because 
 Cloned 3'UTR-pGL3           
             
Dog ID  sample3 (848) sample10(848) sample11 (848) sample13 (848)   sample19 100) sample20 (100) sample22 (100)   
SNP1 67516230 G G G C     G G G     
SNP2 67516211 T T T T     T T T     
SNP3 
                  
67516041 A A A A     G G G     
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of their culture adherence properties, resistance, suitable transfection host, and ability to 
express PTPN3. In our study we used MDKC NBL2 line from ATCC (American Type 
Culture Collection).  Cell line was grown in DMEM (Gibco) supplemented with 10% FBS 
and antibiotics. Cells were cultured in T25 flasks at 37°C in a humidified air/CO2 
atmosphere and passaged after 70- 80% confluence which usually occurred in two days 
(Fig. 5). 
 
 
 
Figure 5. MDCK cells in high confluence. 
 
 
Thawing of cryopreserved cells:  
Stocks of MDCK cell cultures were stored in liquid nitrogen tanks. To revive cells, they 
were transferred to a 37°C water bath for about 2 min then rapidly thawed in 10ml of 
complete medium (DMEM) in a 15ml falcon tube. Cells were centrifuged at 125xg for 5 
min, the supernatant discarded and the remaining pellet resuspended in 10ml of complete 
medium.  Cell suspension was then afterwards transferred to a T-25 flask and incubated at 
the 5% CO2 concentration and 37°C temperature. MDCK cells were maintained in 
Dulbecco’s modified Eagle’s medium, DMEM (Gibco), supplemented with 10% fetal 
calf serum (FCS) (Gibco) and penicillin/streptomycin solution (1%) (Gibco) and L-
Glutamine solution (1%) (Gibco).  Cells in culture T flasks were maintained by periodic 
passaging. When confluence was reached cells were trypsinised and subcultured. 
 
4.7.2 Jurkat Cells  
 
The Jurkat cell line is derived from a T-cell leukemia and was established from the 
peripheral blood of a 14 year old boy by Schneider et al., (year) and was originally 
designated JM. The line was cloned from cells obtained from Dr. Kendall Smith. This is a 
clone of the Jurkat-FHCRC cell line, a derivative of the original Jurkat cell line.  
Jurkat cells are IL-2 producing T lymphocyte cells, commonly used to study T cell 
signaling. Jurkat cells are easy to culture, and grow rapidly (Fig. 6). The base medium for 
this cell line is RPMI Medium (Gibco), and to make the complete growth medium, FCS to a 
final concentration of 10% was added. Cultures were maintained in suspension by the 
addition of fresh medium or replacement of medium. New cultures were also established by 
centrifugation with subsequent resuspension at around 105 viable cells/mL. Incubation was 
maintained at 37°C and 5% CO2 concentration. 
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Figure 6: Jurkat T-Cells in suspension. Low and high confluence intensities 
are shown. 
 
 
4.7.3 Transfection with Plasmid DNA 
 
Transfection is a method to introduce nucleic acids into eukaryotic cells using nonviral 
techniques. Although different approaches can be used for this method, we have 
successfully used lipid technology with Lipofectamine 2000 (Invitrogen).  
 
Plasmid vectors containing luciferase reporter genes can be utilized to effectively quantify 
expression levels in the cells. Reporter gene assays may be performed 1 to 3 days after 
transfection, but usually 48 hours. MDCK cells were previously plated about 24h in 
advance prior to transfection. DMEM medium was aspirated and cells thoroughly washed 
with 10 ml PBS. PBS is carefully aspirated afterwards. Three ml of Trypsin (0,75%) in PBS 
was added to the culture flask and spread evenly and agitated to encourage detachment from 
the flask. Incubation at 37°C for 10-15 min in Trypsin allowed faster detachment of cells. 
Neutralization with 10 ml of complete Medium (DMEM + 10% FBS) without antibiotics 
was pipetted over the cells and pipetted up and down to avoid any cell clumps that may 
have formed. Cell suspension was transferred to a 50 ml falcon tube leaving 1 to 2 ml in the 
original flask to maintain cells stock (after adding 10 ml of complete DMEM fresh medium 
and transferred to incubator).  Complete DMEM medium with antibiotics was added to 
falcon tube where remaining cells were until 25 ml were reached. Cells were centrifuged at 
1200 rpm for 5 min and supernatant removed carefully without disturbing the pellet. 
Detachment of pellet rubbing the tube against a grid and addition of another 20 ml of 
medium for resuspension was preformed prior to cell counting. Cells were manually 
counted with haemocytometer (average of 4 grids), estimating the number of cells of round 
99 x104  /ml. For transfection we needed 500 000 cells (0,5 ml) per well and 24 wells per 
plate. Cell culture plates were incubated at 37°C for 24 hours. 
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4.7.6 Reporter Gene Luciferase 
 
Genetic reporter systems have an important role in the understanding of gene regulation and 
expression of eukaryotes mainly as indicators of transcription activity in cells. The reporter 
construct is inserted in a promoter sequence in a expression vector, in our case the pGL3 
promoter, and transfected to in vitro cells followed by measurement of intensity of 
luciferase protein itself or its enzymatic activity. This type of assay is sensitive, 
quantitative, rapid, reproducible, and allow functional analysis of different elements in the 
genes since the expression of reporter protein is directly correlated with transcriptional 
activity of reporter gene.  The Dual-Luciferase Reporter (DL) Assay System allows making 
efficiently two simultaneous assays. In the DL Assay, the activities of firefly and Renilla 
luciferases are quantitatively measured in a sequence from the same sample. By these 
means firefly luciferase is quantified by adding Luciferase Assay Reagent II to allow 
production of a chemiluminescent signal that is maintained by around one minute followed 
by the Renilla luciferase reaction adding a different reagent to the same sample. The 
luminometer may take as few as 4 sec per sample and is operated by reagent auto-injectors. 
This method is extremely sensitive providing a fast quantification method 
(www.promega.com, accessed May 2013).  
 
4.8 RNA Degradation Assay in Jurkat T cells 
 
The amount of mRNAs in the cell is the final result of mRNA synthesis and degradation. 
Reporter gene expression profiling experiments like the ones we performed in this project, 
indirectly take a snapshot of the total amount of mRNA levels and protein translation in the 
cell and do not capture all the dynamics of mRNA synthesis and breakdown during a certain 
amount of time ('t Hoen et al., 2010). The current assay determines and surveys mRNA 
degradation rates during a 12 hour period in specific time point intervals, for the Jurkat cells 
transfected with 3’UTR inserts. 3′-UTRs with different polymorphisms like those we 
studied here, may contribute to differential stability of transcripts and degradation rates of 
luciferase expression that might possibly change according to the different risk and 
protective variants, although final expression analysis seem to be similar between them. 
RNA measurement was performed by reverse transcribing RNA into cDNA, and quantify it 
with quantitative real time PCR (qPCR). 
 
Jurkat T cells were grown in proliferation medium RPMI supplemented with 10% FBS 
without antibiotics and transfected with 1.4 μg of construct DNAs from the two protective 
and risk haplotypes as well as control transfections with pGL3 promoter vector without 
constructs, and 3.5 μg of Lipofectamine 2000 per well, each containing approximately 1,6 
million cells. Cultures of transfected proliferating Jurkat cells were left incubating in 12-
well dish plates for 24 hours containing 2-ml medium and activated with PMA+IO 5 hours 
after transfection according to same protocol used for pilot assay previously described. This 
period of time allows activation of all possible pathways for 3’UTR mRNA degradation 
including miRNA. After 10 hours of PMA+IO activation, 3 μl at  10 ηg/ml (per well) of 
actinomycin D was started to be added to arrest the transcription machinery and de novo 
RNA synthesis, at five different time points after addition of initial actinomycin D treatment 
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(0, 2, 4, 8 and 12 hours). RNA was extracted from around 800,000 cells/ well and DNA 
extracted from around 720,000 cells /well. 
 
4.8.1 Two-step RT-qPCR 
 
The quantification of mRNA using Reverse Transcription quantitative Real Time PCR (RT-
qPCR) was performed using a two-step reaction. In this case it required that the RT reaction 
and qPCR amplification were performed in separate tubes. One major advantage of this 
approach is high reproducibility of the analysis. This method is also good when using DNA 
binding dyes like the one used, SYBR Green since the elimination of primer-dimers can be 
achieved by a simple change in the melting temperature (Wong et al., 2005).  
 
RNA was isolated with TRIzol Reagent (Invitrogen) according to manufacturers 
instructions. After removal of growth media from culture dishes we added 1 ml TRIzol 
Reagent directly to the cells in the culture dish and cells were lysed directly by pipetting up 
and down several times. 0.2 mL of chloroform were added and used for homogenization 
shake tubes vigorously by hand for 15 sec.  After 3-4 min incubation at room temperature 
samples were spun at 12,000 × g for 15 min at 4°C. Afterwards, we removed the aqueous 
phase of the sample by angling the tube at 45° and pipetting the solution out avoiding 
drawing any of the interphase or organic layer into the pipette when removing the aqueous 
phase. And transferred into new labeled eppendorf tubes. 0.6 mL of 100% isopropanol were 
added to the aqueous phase, and incubated at room temperature for 30 min and spun down 
at 12,000 × g for 15 min at 4°C. Finally, the supernatant was removed from the tubes and 
RNA pellet washed with 1 ml of ethanol 75%, vortexed briefly and centrifuged at 7500 x g 
for 5 min at 4°C. Wash was discarded and procedure was repeated once. We have made a 
final washing with 99% ethanol followed by a 3 min centrifugation at 7500 x g to allow for 
a better pellet drying. For RNA resuspension 25 μl of RNase-free water were added to the 
RNA pellet. 
 
Since we convert the RNA back into DNA via reverse transcriptase, and then attempt to 
amplify and quantify target luciferase that is expressed in Jurkat T cells, any genomic DNA 
present could also be potentially amplified, leading us to question whether the final results 
of RT-qPCR are due to the cDNA that we want to generate, or potentially the presence of 
contaminating genomic DNA.  To prevent this, RNA samples were treated with DNase, an 
enzyme that selectively degrades DNA according to the following protocol: 
 
 
Reaction Components  
RNA                                          6 μl         
RQ1 DNase buffer  (Promega) 2 µl 
RQ1 DNase  (Promega)           1.5 µl 
Nuclease-free water to bring a total volume of 20 µl 
 
Samples were incubated at 37°C for 55 min after which 2 μl of Stop Solution EGTA and 
incubated again at 65°C for additional 10 min to inactivate DNase. DNA was extracted to 
be used as “control” or for normalizing amounts of cDNA derived from RNA of 
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corresponding cell samples, in order to give us better reproducibility of results, calculating 
amplified cDNA/ DNA ratio. DNA extraction was performed using DNeasy Blood and 
Tissue (QIAGEN) according to manufacturer’s recommendations. Around 100,000 cells per 
well were centrifuged for 5 min at 300 x g and the pellet resuspended in 200 μl PBS. 20 μl 
proteinase K and 4μl RNAse A at 30 mg/ml were added and left incubate for 2 min at room 
temperature. We added 200 μl Buffer AL (without added ethanol) and mixed thoroughly by 
vortexing. Samples were incubated at 56°C for 10 min, proceeded by addition 200 μl 
ethanol (99%) to the sample, and mixed thoroughly again by vortexing. The mixture was 
then pipetted into the DNeasy Mini spin column placed in a 2 ml collection tube and 
centrifuged at 8000 rpm for 1 min. The flow-through and collection tube were discarded 
and the DNeasy Mini spin column was placed in a new 2 ml collection tube and 500 μl of 
Buffer AW1 was added and centrifuged again for 1 min at 8000 rpm. Both flow-through 
and collection tube were discarded after this step. We placed the DNeasy Mini spin column 
in a new 2 ml collection tube and added 500 μl of Buffer AW2, and spin down for 3 min at 
14,000 rpm in order to dry the DNeasy membrane. Again, the flow-through and collection 
tube were discarded in order to assure the membrane was left dry to assure no residual 
ethanol was left. Elution was carried by placin the DNeasy Mini spin column in a clean and 
properly labeled 1.5 ml o microcentrifuge tube, and by pipetting 200 μl of Buffer AE 
directly onto the DNeasy membrane and left Incubate at room temperature for 2 min. 
Centrifugation for 1 min at 13000 rpm allowed us to finally collect DNA from cell samples 
and estimate DNA concentration from all samples with nanodrop. 
 
4.8.2 Reverse Transcription (RT) 
 
RT reaction is also called first strand cDNA synthesis. Single-stranded RNA was reverse 
transcribed into cDNA by using 4 μl of the total cellular RNA or poly(A) RNA, 2 μl of RT 
Buffer II, 0.8 μl MULV-RT (Clontech) reverse transcriptase enzyme, 0.8 μl dNTPs (25 
mM) and 0.4 μl RNase inhibitor. Two types of primers were used for RT reaction: oligo 
(dT) primers 0.5 μl and 1 μl of random (hexamer) primers in a final volume of 20 μl in PCR 
tubes. RT reaction was left incubate 10 min at room temperature and extended at 42° for 80 
min and finally heated at 95° to inactivate the enzyme for 5 min. The resulting cDNA could 
then be used in qPCR reaction. 
 
4.8.3 qPCR with SYBR green  
 
Luciferase primer sets were used to target our samples for the real‐ time PCR reaction. 
SYBR green reagent was also used allowing detection of increases in DNA per cycle as 
binding double stranded DNA is being synthetized and light is emitted when excited. The 
light emitted during the process is quantified and used to determine the abundance of the 
gene product in the samples. Extracted DNA samples were diluted 1:500 (final 
concentration ± 50 pg/μl) and reverse transcribed RNA (cDNA) diluted 2 times in deionized 
water. 
A MicroAmp optical 384-Well Reaction Plate (Applied Biosystems) were loaded in 
duplicates and for both cDNA and DNA with 19 μl of SYBR green master mix according to 
the following protocol (for each cDNA/ DNA sample): 
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cDNA/ DNA                                         1 μl 
H2O                                                14.2 μl 
Primer F Luc (Thermo Scientific)     0.4 μl 
Primer Rev Luc (Thermo Scientific) 0.4 μl 
10x PCR Rxn Buffer (Invitrogen)        2 μl 
MgCl2 (1.5 mM final concentration) 0.7 μl 
dNTPs                                                0.8 μl 
Plat-Taq                                             0.1 μl 
SYBR green (Invitrogen)                  0.4 μl  
 
Total                                                   20 μl 
 
Plate was loaded in a 7900 Fast Real-Time PCR System (Applied Biosystems) and PCR 
program set up according to following: 
 
                      95° 5min 
               45 cycles 
                      95° 15s 
                      62° 15s   
                      72° 20s  
      Melting Curve 
                      95° 15s  
                      62° 15s  
 
5 RESULTS  AND DISCUSSION OF BIOINFORMATICS AND FUNCTIONAL 
ANALYSIS  
 
5.1 Bioinformatics and Molecular Analysis of PTPN3 intron 18 
 
The first stretch of the sequence of intron 18 comprising around 2,000 bp of PTPN3 gene 
was screened with different bioinformatics tools and databases in order to assess constraint 
regions and regulatory elements associated with 8 identified SNPs in this region to establish 
possible associations between the different SNP haplotypes and functional regulatory 
elements.   
 
The sequence was initially screened on Santa Cruz database using Broad/canFam2 
assembly and compared with Human hg/18 for constrained elements. Sequence was 
analyzed with different databases for SNP conservation, functional elements, consensus, 
conserved transcription factor binding sites and constrained elements and motifs between 
Dog, Human, Mouse and Rat and again between 29 mammals. A number of tracks were 
taken into consideration for this analysis.  
 
The two identified constraint regions among 29 mammals were screened with TESS, 
CONCITE, TFSearch for Transcription Factor Binding Sites (TFBS). The regions were also 
screened with the software Sequence Manipulation Suite- DNA Finder 
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(http://bioinformatics.org/sms) for identifying DNA patterns and motifs. On the highest 
conserved region CONSITE detected the presence of  2 TFBS for AML 1 (cutoff  85 %).  
AML1 binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, 
including T-cell receptor enhancers. However, there were no consistent results between 
CONSITE and TESS. The first highly conserved region however does not reveal any 
binding sites or significant pattern or motif. This highly constrained region may be 
associated with additional TFBS, novel regulatory features or simply chance of stretches of 
sequence similarity. 
 The other conserved regions observed between Dog, Human, Mouse and Rat, were 
screened by TESS and CONSITE for putative TFBS and all revealed to have in common a 
GATA 3 binding motif within their regions for selected thresholds above 80% detected both 
in positive and negative strands. Similar screening was performed along the whole 2Kb 
sequence by CONCITE for GATA 3 with a transcription factor score cutoff of 90% and the 
results predict more putative sites along first 1Kb region (fig. 7). 
Since GATA 3 is a transcription factor that is known to be functional for the TCR-beta –
transcriptional enhancer and it binds to several T-cell receptor regulatory elements, this 
transcription factor was screened more cautiously around this whole region. TFBS 
GATA patterns were screened in the whole 2kb region by Sequence manipulation Suite 
software and 4 100% matches were found in the region around first 4 SNPs against 1 
GATA match for second region around the other 4 SNPs, suggesting higher affinity for 
GATA family for first 1kb of intron 18. 
 
 
Figure 7. CONSITE analysis of TFBS GATA 3 along 2Kb region 
of intron 18, cutoff 90%. 
 
In order to have a more precise functional insight around the identified SNPs, stretches of 
sequences of around 15 bp upstream and 15 bp downstream for each SNP and for both 
alleles were analyzed for TFBS prediction and the most striking results seem to be around 
SNP 67538032 (first) and SNP 67397924 (third) where presence of T alleles on these SNPs 
predict high scorings for TF GATA 3 against lower affinities for other alleles (Table 6). 
Besides, in all screened databases T alleles for both first and third SNPs seem to show 
affinities for higher number of many other different TFs than G or C alleles, even at higher 
cutoffs (> 85%). 
 
 
 
 
 
SNP allele score sequence 
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67538032 
G (protective) 5.421 AAATGGAGTGTGTGTATCTTCTAAAT 
T (risk) 7.189 AAATGGAGTGTGTTTATCTTCTAAAT 
67537924 C (protective) 0 
TAGATCGTGATTAGCGACTACTTACAGAGTC 
A (risk) 0 TAGATCGTGATTAGAGACTACTTACAGAGTC 
67537493 T (risk) 8.092 
GGAGTACTATCATTACTTGG 
C (protective) 3.693 GGAGTACTACCATTACTTGG 
67537177 
A (protective) 0 GGGCTCATTCAGC 
G (risk) 0 GGGCTCGTTCAGC 
67536944 
C (protective) 0 GTCCTCCGGGGTGAGA 
T (risk) 0 GTCCTCTGGGGTGAGA 
67536642 
A (protective) 0 CCCTCCATGCGGCCAGC 
C (risk) 0 CCCTCCCTGCGGCCAGC 
Table 6. CONCITE  (http://asp.ii.uib.no:8090/cgi-bin/CONSITE, accessed Feb. 2013) analysis for TFBS GATA 3 
around  all SNPs. (red highlights the 2 top associated SNPs in this region) 
 
According to TESS the position of T allele in SNP 67538032 determines 100% consensus 
for transcription factor FOXI 1 on that position, meaning that this TF is not predicted in 
other allele. Regarding top most associated SNP 67537177, G allele seems to have a 100% 
consensus for that nucleotide for both p53 and RAR. Since transcription factors rarely act 
alone in regulating gene expression and, many times, multiple factors may bind the DNA in 
close proximity to each other forming regulatory modules integrating multiple signals. The 
identification of GATA modules and higher-order regulatory structures around first and 
third SNPS may eventually be an important finding during this computational analysis of 
regulatory elements in intron 18 of PTPN3. Intronic Splicing Sites were also analyzed and 
for all SNP variants in intron 18 and results compared using different bioinformatics 
platforms. Human Splicing Finder software detected an introduction of 2 new silencer 
motifs in SNP 67538032 where there is a mutant sequence substitution at G>T. This site is 
however outside of the known exon/intron junction. 
 
As for molecular analysis of Intron 18, and due to time restrictions the experiment couldn’t 
be completed and we could only clone the two constructs from the risk haplotype. 
Protective haplotype had very low concentration yields of final purified and digested intron 
18 amplicons (± 3 ηg/μl), not allowing to proceed with sufficient amounts for the pGL3 
ligation step. 
 
 
5.2 Bioinformatics Analysis of PTPN3 -3’UTR 
 
The 3'-UTR is very important in gene expression by influencing the localization, stability, 
export, and translation efficiency of the mRNA. It has a number of sequences associated 
with gene expression, like microRNA response elements, AU-rich elements (ARE), IRON-
responsive elements, cytoplasmic polyadenylation elements and the poly(A) tail. 3’UTR 
structural characteristics as well as its use of alternative polyadenylation strengthens its role 
in gene expression (Barrett et al., 2012). Mutations in this region can have strong 
consequences because one change can be secondarily responsible for the altered expression 
of different genes. In other words, during transcription a mutation may affect not only the 
allele and genes that are physically linked but also binding proteins that are related to the 
processing and nuclear export of mRNA affecting other unrelated genes (Chatterjee et al., 
2009). 
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3’UTR in the canine PTPN3 is 3452 bp length and 82% sequence similarity compared to 
human having many regions highly conserved between human/ mouse/ rat. Although none 
of the studied SNPs are included in these regions, they are flanking the polymorphic sites 
very closely (http://genome.ucsc.edu/index.html, accessed 22 May 2013). SNP rs22128547 
(top most associated in 3’UTR region) is located in a region of constrained elements 
between 29 eutherian mammals predicting the existence of important regulatory elements 
around its location. 
 
For the bioinformatics analysis different databases were used to determine different UTR 
motifs like potential predicted microRNA targets, ARE and poly(A) elements, to determine 
in silico if polymorphisms might have any causal effect. However, no evidence of direct 
influence of any of the studied SNPs with direct overlapping of any of the elements was 
found. For prediction of microRNA targets, TargetScanHuman database was used and 
retrieved information shows that targets are closely located both upstream and downstream 
of the SNPs but never overlapping them (Fig. 8). The target site with highest conservation 
score is the cfa-mir-145 and it happens to be simultaneously the closest (90bp downstream 
to the SNP rs22128547) (http://www.targetscan.org, accessed online 20 May 2013). 
 
 
Figure 8. Conserved sites for miRNA families broadly conserved among vertebrates relative to 
Dog PTPN3 3’UTR. Blue arrows indicate SNP positions (http://www.targetscan.org, accessed 
March 2013). 
 
Thermodynamic prediction of mRNA folding in 3’UTR region containing the two different 
alleles A and G for SNP rs22128547 was done using RNAfold webserver 
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi, accessed June 2013) in order to estimate 
possible secondary structure changes between the two variants. Results showed that there is 
an evident change in the stem loop where polymorphic site is located (Fig. 9). 
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This change in mRNA secondary folding may potentially represent a dramatic change in de-
regulation during translation or other important events during gene expression. RNA 
secondary structures have a preponderant influence in the function of different types of 
RNAs, like mRNAs and microRNAs in almost every step in gene expression (Seemann et 
al., 2008). 
  
5.3 Results from Functional Molecular Analysis of PTPN3 – 3’UTR 
 
5.3.1 Optimization and Transfection for MDCK cells 
 
Prior to transfection the plated cells were examined under the inverted microscope to ensure 
cells were 80% confluent.  Optimization assay for MDCK cells with pGL3+ Renilla (pRL-
TK) was preformed prior to final experiment in order to establish the optimal amount of 
DNA/ lipofectamine 2000 to be used in relation to two different concentrations Renilla 
pRL-TK, 50 ηg and 100 ηg A ratio of 1/2.5 of pGL3/Lipofectamine 2000 was kept all 
times.  Protocol was developed according to Table 4. 
 
Lipofectamine 
2000 2.5 μl 2 μl 1.5 μl 0.75 μl 
pGL3 +pRL-TK 
(total) 1 μg 0.8 μg 0.6 μg 0.3 μg 
PGL3 + Renilla 
pRL-TK 
0.9 μg 
/100ηg 
0.95 
μg 
/50ηg 
0.7 μg 
/100η
g 
0.75 μg 
/50ηg 
0.5μg 
/100ηg 
0.55 
μg 
/50ηg 
0.2 μg 
/100ηg 
0.25 
μg 
/50ηg 
Table 4. Transfection optimization assay for Dual luciferase / Renilla expression with 1/25 ratio Lipofectamine 2000 
in MDCK cells. 
 
Fresh dilutions of plasmids were made as required before each transfection experiment 
(starting up with initial concentration of 671 ηg/ μl for pGL3 and 406 ηg/ μl for Renilla 
pRL-TK expressing vectors). Separate master mixes were made for each plasmid being 
transfected, and different amounts of Lipofectamine 2000/Opti-Mem mix reagent per 
reaction were made and incubated at room temperature for 5 min in the filtered hood.  
Specified amounts of Lipofectamine 2000 /Opti-Mem mix was then added to each of the 
reporter/Opti-Mem mixes and incubated at room temperature in the filtered hood for 
another 20 min. Transfection mix was added in duplicates in one 24 well plate. Cells were 
Figure 9. Thermodynamic 
prediction of secondary folding 
of mRNA for the polymorphic  
site A/G in SNP rs22128547 
from 3’UTR of PTPN3 gene 
(http://rna.tbi.univie.ac.at/cgi-
bin/RNAfold.cgi, accessed online 
3 June, 2013). 
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then incubated for 48h. For final transfection of MDCK cells we have used 400 ηg of total 
DNA plus 50 ηg of pRL-TK (1 μl). In order to achieve the same amounts of DNA, different 
volumes were used. Three independent DNA preparations in order to increase repeatability 
of results since many factors may interfere with DNA purity. 50 μl of Opti-Mem were 
added to 400 ηg of DNA and 50 ηg of pRL-TK in 7 separate and labeled eppendorf tubes 
and 50 μl of Opti-Mem plus 1,125 μl of Lipofectamine 2000 (ratio 1:2.5) were left 
incubated at room temperature for 5 min. After this time, both DNA+pRL-TK and 
Lipofectamine were combined and left again incubate for another 20 min at room 
temperature. DNA/pRL-TK/Lipofectamine 2000 combination was added to each of 24 well 
plates loaded in triplicates for each DNA sample plus controls with pGL3. Cells were left 
for transfection in incubator for 48h at 37°C and 5% CO2. After this period cells were lysed 
and collected from the 24 well plates scratching the bottom with pipette tips and transferred 
to properly labeled eppendorf tubes. Cells were centrifuged for 2 min at 3000 rpm. 
Supernatant was discarded and cells were resuspended in PBS (700 μl) and centrifuged 
again for 2 min at 3000 rpm. Supernatant was discarded by suction pump and 90 μl of lysis 
buffer added to each tube followed by low speed vortexing and left 15 min at room 
temperature. Finally the lysed cells were spun for 30 sec and supernatant collected for Dual-
Luciferase assay.  
 
5.3.2 Pilot assay for Transfection of Jurkat cells 
 
In order to assess transfection efficiency, two different batches “A” and “B” of Jurkat T-
cells were cultured in RPMI + 10% FBS without antibiotics and divided in two subgroups, 
one stimulated with Phorbol 12-Myristate 13-Acetate (PMA) and Ionomycin (IO) and 
another one non-stimulated. PMA and IO are both immunogenic activators allowing 
Calcium flux leading to several downstream effects, such as up-regulation of CD7 in T cells 
(signal of activation) or the hydrolysis of phosphoinositides and activation of protein kinase 
C in T-cells. Activation of PMA+IO was performed 10 hours prior to collection and 24 hour 
after transfection. Stimulation was done with 2 μl of PMA at final concentration of 20 
ηg/ml and IO with 0.5 μl at 0.5 mM.  Transfection of pGL3 promoter and pRL-TK was 
done in two different amounts (300ηg/100ηg and 600ηg/200ηg) for both subgroups and 12 
wells (600.000 cells/well) of a 24 well plate was used according to Table 5. 
 
pGL3/pRL-TK Non Stimulated (NS) 
Stimulated 
(PMA+IO) 
 
300ηg/100ηg 1 2 9 (NS Cells) Batch A 600ηg/200ηg 3 4 10 (Stimulated Cells) 
300ηg/100ηg 5 6 11 (NS Cells) Batch B 600ηg/200ηg 7 8 12 (Stimulated Cells) 
 
Table 5. Distribution scheme of 2 different batches of Jurjat T-cells in 12 wells both stimulated and non-stimulated 
with PMA+IO and with different pGL3/pRL-TK amounts. 
 
5.3.3 DUAL Luciferase Assay Analysis for 3’UTR in MDCK cells 
 
Data obtained from reporter analysis from the two independent experiments was analyzed 
and compared between the 3 different 3’UTR variants of PTPN3 in MDCK cells. 
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Unpaired t test results between protective G/A and C/A and risk G/G haplotypes: 
 
P value and statistical significance G/A versus G/G:  
The two-tailed P value between protective haplotype G/A versus Risk haplotype G/G equals  
0.8121. By conventional criteria, this difference is considered not to be statistically significant.  
 
P value and statistical significance C/A versus G/G:  
The two-tailed P value between Protective haplotype C/T/A versus Risk haplotype G/T/G  
equals 0.5945. By conventional criteria, this difference is considered not to be statistically  
significant. 
Luciferase analysis did not reveal a trend in Luciferase expression regarding different insert 
haplotypes. There are no consistent results that may give indication that protective and risk 
3’UTR variants play a distinct role in PTPN3 gene regulation or expression (Fig. 10). 
 
 
 
Figure 10. Reporter analysis of the 3’- untranslated region (3’UTR) of PTPN3. The entire 1.6 
kb region was cloned and inserted after the firefly luciferase in a pGL3 vector. Luciferase 
activity was examined. Bars show the mean results from 2 independent experiments. The firefly 
luciferase containing G/A construct has P=0.81 versus G/G, and C/A has P=0.59 versus G/G. 
 
 
5.3.4 DUAL Luciferase Assay Analysis for 3’UTR in Jurkat T-cells  
 
Data obtained from reporter analysis from the two independent experiments was analyzed 
and compared between the 3 different 3’UTR variants of PTPN3. 
 
Unpaired t test results between Non Stimulated Protective C/A and Risk G/G 3’UTR 
P value and statistical significance:  
  The two-tailed P value equals 0.372. By conventional criteria, this difference is not 
considered to be statistically significant.  
Unpaired t test results between Non Stimulated Protective G/A and Risk G/G 3’UTR 
0,52 
0,54 
0,56 
0,58 
0,6 
0,62 
0,64 
0,66 
G/A C/A G/G 
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P value and statistical significance:  
  The two-tailed P value equals 0.5472. By conventional criteria, this difference is not considered to 
 be statistically significant.  
Unpaired t test results between Stimulated Protective G/A and Risk G/G 3’UTR 
P value and statistical significance:  
  The two-tailed P value equals 0.7663. By conventional criteria, this difference is not 
considered to be statistically significant.  
Unpaired t test results between Stimulated Protective C/A and Risk G/G 3’UTR 
P value and statistical significance:  
  The two-tailed P value equals 0.8653. By conventional criteria, this difference is not 
considered to be statistically significant.  
Once again, Luciferase analysis did not reveal a trend in Luciferase expression regarding 
different insert haplotypes in Jurkat cells. There are no consistent results that may give 
indication that protective and risk 3’UTR variants play a distinct role in PTPN3 gene 
regulation or expression (Fig. 11). 
 
  
 
 
 
Figure 11. Reporter analysis of the 3’UTR of PTPN3 for Jurkat T-cells stimulated with 
PMA+IO (ST) and non-stimulated (NS). The entire 1.6 kb region was cloned and inserted after 
the firefly luciferase in a pGL3 vector. Luciferase activity was examined. Bars show the mean 
results from 2 independent experiments in a total of 6 replicates. In experiments with the firefly 
luciferase in ST cells, G/A construct has P=0.372 versus G/G, and C/A has P=0.54 versus G/G. 
In ST cells we verified that protective G/A construct has P=0.86 versus risk G/G and protective 
C/A has P=0.76 versus risk G/G. pGL3 promoter was used without 3’UTR insert as a control 
where higher levels of protein expression with P=0.0086 versus protective G/A construct. SEM 
error bars are indicated. 
 
0 
0,1 
0,2 
0,3 
0,4 
0,5 
0,6 
NS          ST             NS           ST              NS              ST           NS              ST 
Protective C/A Protective G/A 
 
 Risk G/G pGL3 promoter 
(control) 
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6 CONCLUSIONS AND FUTURE DIRECTIONS  
 
The present investigation aimed to validate the association of PTPN3 -3’UTR and intron 18 
regions containing some of the top highly associated SNPs to lower expression levels of this 
protein in IMRD in NSDTRs.  
 
Luciferase expression levels in different haplotypes of 3’UTR did not reveal any trend and 
p values are not statistically significant between any of the protective and risk variants in 
the transfected MDCK and Jurkat T cells. As expected and as it is observed in most cells 
and tissues, PTPN3 protein is lowly expressed in transfected cells and that may be due to 
the presence of two ARE elements in 3’UTR that rapidly degrade mRNA. 
 
To corroborate this hypothesis, RNA degradation analysis is still ongoing and might 
provide additional information about the dynamics of mRNA synthesis and degradation 
during several time-points during a 12 h time period. Since bioinformatics analysis revealed 
the presence of SNP rs22128547 within a highly constrained region it supports the fact that 
conformational change in thermodynamic secondary folding of mRNA for the polymorphic 
site (transition that exchanges a purine for purine (A ↔ G) ) may potentially represent a 
dramatic change in de-regulation during important events in gene expression. The 
development of this research may provide insights into the complexity of PTPN3 
expression. Additional experiments should be designed to clarify clearly if this region may 
play an important role in diseased haplotypes with for example further cloning of 3UTR 
inserts without one or both ARE elements that may potentially be overshadowing luciferase 
expression as we can clearly see in figure 11 by comparing protective and risk haplotypes 
with the control promoter pGL3.  
 
To define the functional role of Intron 18 polymorphisms, ongoing experiments as outlined 
above must be proceeded and data analysed comparing both protective and risk haplotypes 
in luciferase expression. However, in silico analysis revealed some important clues about a 
specific highly conserved region comprising around 1 Kb, in which the identification of 
multiple GATA modules and higher-order regulatory structures around first and third SNPs 
may eventually be an important finding during computational analysis of regulatory 
elements in intron 18. Several diseases including autoimmune, have been already associated 
with intronic polymorphisms like autoimmune thyroid disease (Liu et al. 2012), SLE, and 
rheumatoid arthritis (Alfadhli, 2013) 
Further development of research on intron 18 should be continued in order to uncover 
potential influence of this region in disease haplotypes over PTPN3 expression. 
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